News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AB Science (AB.PA) Release: European Medicines Agency Accepts Marketing Application for Masitinib in the Treatment of Gleevec® Resistant Gastro-Intestinal Stromal Tumor



10/4/2012 10:15:42 AM

PARIS--(BUSINESS WIRE)--Regulatory News: AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announced that the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for masitinib in the treatment of patients with Gleevec®-resistant gastro-intestinal stromal tumors (GIST).

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES